Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 2/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL982424 | 1.00 | GAA (0.46) | GAAKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL11946796 | 0.87 | PABPC1 (0.40) | GAAMEN1KMT2APABPC1EIF4H | |
| SCHEMBL982681 | 0.87 | PABPC1 (0.40) | GAAMEN1KMT2APABPC1EIF4H | |
| SCHEMBL982682 | 0.87 | PABPC1 (0.40) | GAAMEN1KMT2APABPC1EIF4H | |
| SCHEMBL984879 | 0.83 | KDM4E (0.43) | GAAKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL984878 | 0.83 | KDM4E (0.43) | GAAKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL985740 | 0.81 | GAA (0.64) | GAAKDM4EALDH1A1LMNAMEN1 | |
| SCHEMBL985508 | 0.79 | PRKCI (0.39) | KDM4EALDH1A1LMNAPRKCINAPRT | |
| SCHEMBL985507 | 0.79 | PRKCI (0.39) | KDM4EALDH1A1LMNAPRKCINAPRT | |
| SCHEMBL13593419 | 0.74 | CHRNA7 (0.46) | LMNAMEN1KMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | GAA 1570/4885KDM4E 1069/4885ALDH1A1 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.